On November 15, 2022 xCures reported that they will present two posters at the 27th Annual Meeting of the Society for Neuro-Oncology, from the 16th to the 20th of November 2022, in Tampa Bay, Florida (Press release, xCures, NOV 15, 2022, View Source [SID1234624099]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Society for Neuro-Oncology is a multidisciplinary society of healthcare professionals dedicated to promoting advances in neuro-oncology through research and education. Their annual meeting features research and educational sessions on brain tumors, including the latest on diagnosis and treatments.
The two xCures posters will be presented at the Poster Session on Friday, November 18, 2022, from 7:30 pm-9:30 pm EST, and are entitled:
EPCO-10: Systems biology-based therapeutic predictions with gbmSYGNAL and clinical correlates in the real-world longitudinal outcomes registry XCELSIOR
Timothy J. Stuhlmiller, Serdar Turkarslan, Julie C. Friedland, Asher Wasserman, Jameson Quinn, Zac Cole, Alaa Awawda, Sabrina Irizarry, Sebastian Williams, Mark Shapiro, Santosh Kesari, Anoop P. Patel, Nitin S. Baliga
BIOS-03: Real world clinical outcomes of patients with diffuse midline glioma in a longitudinal outcomes registry
Timothy J. Stuhlmiller, Asher Wasserman, Jameson Quinn, Zac Cole, Alaa Awawda, Sabrina Irizarry, Sebastian Williams, Mark Shapiro, Al Musella, Santosh Kesari
"I’m proud to present these analyses of real-world data and clinical outcomes of CNS cancer patients from our observational registry," stated xCures’ VP of Scientific and Medical Affairs Timothy J. Stuhlmiller. "Together with leading neuro-oncologists and computational biologists, we are bringing evidence-based insights to the treatment of brain cancer patients."
The xCures platform generates Real-time, Regulatory-grade, Clinical data (RRC). It now includes data on over 1,000 brain cancer patients, permitting real-time insight into which treatments show the most promise across patient cohorts.
Emerging data on investigational and off-label interventions will be presented for patients with diffuse midline glioma (DMG), along with data from a partnership with the Institute of Systems Biology (ISB) integrating real-world clinical outcomes with a systems biology algorithm for treatment predictions to identify rational treatment options for glioblastoma patients.